Table 6. Details of 18 complete... | American Society of Hematology

Table 6.

Details of 18 complete responders

	Diagnosis	Status SCT	Age	Sex	Maximum DLI dose	Days after SCT	GVHD	Days to CR	Survival, d	Other/cause death
1	CML	CP1	46	F	10⁷	227	AII, CExt	144	477+
2	HD	PR	36	M	10⁶	107	AIII, CExt	330	474+
3	NHL-F	PR	47	M	5 × 10⁶	76	NIL	660	1170+	MR
4	NHL-F	SR	48	M	2 × 10⁷	311	AII, CExt	67	1099+	MR
5	NHL-F	SR	44	M	3 × 10⁷	124	NIL	49	920+
6	NHL-F	PR	49	M	10⁷	358	AIII, CExt	120	687	GVHD
7	NHL-F	RR	30	M	5 × 10⁷	354	AII, CExt	110	464+
8	NHL-HG	SR	35	M	10⁷	115	AIII, CExt	270	803+
9	CML	CP1	50	F	10⁶	547	NIL	43	677+
10	MDS	UR	54	M	10⁷	75	AIII	47	205	Fungus
11	AML	SR	57	F	10⁷	100	AIV, CNE	53	190	GVHD
12	CML	CP1	45	F	10⁶	209	CLim	80	322+
13	CML	CP2	57	M	10⁶	135	AII, CExt	182	409+
14	NHL-F	SR	34	M	10⁷	120	AIII	569	1037+
15	NHL-F	SR	50	F	10⁷	76	NIL	93	927+
16	T-PLL	PR	51	M	5 × 10⁷	168	CExt	267	700+
17	NHL-F	CR1	53	M	2 × 10⁷	419	NIL	102	629+
18	NHL-MC	CR3	43	M	5 × 10⁷	317	AII, CExt	203	844+

	Diagnosis	Status SCT	Age	Sex	Maximum DLI dose	Days after SCT	GVHD	Days to CR	Survival, d	Other/cause death
1	CML	CP1	46	F	10⁷	227	AII, CExt	144	477+
2	HD	PR	36	M	10⁶	107	AIII, CExt	330	474+
3	NHL-F	PR	47	M	5 × 10⁶	76	NIL	660	1170+	MR
4	NHL-F	SR	48	M	2 × 10⁷	311	AII, CExt	67	1099+	MR
5	NHL-F	SR	44	M	3 × 10⁷	124	NIL	49	920+
6	NHL-F	PR	49	M	10⁷	358	AIII, CExt	120	687	GVHD
7	NHL-F	RR	30	M	5 × 10⁷	354	AII, CExt	110	464+
8	NHL-HG	SR	35	M	10⁷	115	AIII, CExt	270	803+
9	CML	CP1	50	F	10⁶	547	NIL	43	677+
10	MDS	UR	54	M	10⁷	75	AIII	47	205	Fungus
11	AML	SR	57	F	10⁷	100	AIV, CNE	53	190	GVHD
12	CML	CP1	45	F	10⁶	209	CLim	80	322+
13	CML	CP2	57	M	10⁶	135	AII, CExt	182	409+
14	NHL-F	SR	34	M	10⁷	120	AIII	569	1037+
15	NHL-F	SR	50	F	10⁷	76	NIL	93	927+
16	T-PLL	PR	51	M	5 × 10⁷	168	CExt	267	700+
17	NHL-F	CR1	53	M	2 × 10⁷	419	NIL	102	629+
18	NHL-MC	CR3	43	M	5 × 10⁷	317	AII, CExt	203	844+

Only patient 13 received stem cells from an unrelated donor.

HD, indicates Hodgkin disease; F, follicular; HG, high grade; MDS, myelodysplastic syndrome; T-PLL, prolymphocytic leukemia; MC, mantle cell; CP1, first chronic phase; AII, acute GVHD grade II; CExt, extensive chronic GVHD; NIL, none; MR, molecular remission; SR, sensitive relapse; AIII, acute GVHD grade III; RR, resistant relapse; UR, untested relapse; AIV, acute GVHD grade IV; CNE, not evaluable for chronic GVHD; CLim, limited chronic GVHD; CP2, second chronic phase; and CR3, third complete remission.

View Large

This Feature Is Available To Subscribers Only